Can I read Radioimmunotherapy for Marginal Zone Lymphoma on EtoBox?

Radioimmunotherapy for Marginal Zone Lymphoma by paramveer is a document available to read on EtoBox.

What is Radioimmunotherapy for Marginal Zone Lymphoma about?

This Phase II study evaluated the safety and efficacy of 90Y ibritumomab tiuxetan as upfront therapy in patients with previously untreated marginal zone lymphoma (MZL). Among 16 enrolled patients, the overall response rate at 12 weeks was 87.5%, with a median progression-free survival of 47.6 months and a 5-year overall survival rate of 71.8%. The treatment was well tolerated, indicating potential for long-term responses in MZL patients.

Author

paramveer

Language

EN